Side-by-side · Research reference
AHK-CuvsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED14/43 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
AHK-Cu
Tripeptide-Copper Complex · Cosmetic
Topical · Scalp / Skin
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
AHK-Cu
PNC-27
Primary target
Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
—
N/A — cytotoxic mechanism, not signaling modulation
Origin
Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
—
—
02Dosage Protocols
Parameter
AHK-Cu
PNC-27
Effective concentration (in vitro)
10⁻¹² – 10⁻⁹ MPyo 2007
Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.
—
Topical formulation
0.001–0.01% (estimated cosmetic range)
No standardized human protocol published — extrapolated from in vitro data.
—
Frequency
Once or twice daily (topical application)
—
Route
Topical — scalp or dermal application
—
Duration
Not established — cosmetic protocols typically 8–12 weeks
—
Clinical status
—
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
03Metabolic / Fat Loss Evidence
Parameter
AHK-Cu
PNC-27
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
AHK-Cu
PNC-27
Local irritation
Mild erythema, pruritus at application site (copper peptide class effect)
—
Copper sensitivity
Rare hypersensitivity reaction in copper-sensitive individuals
—
Systemic absorption
Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses
—
Data limitations
No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)
—
Human safety data
—
None available — no human trials conducted
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
AHK-Cu
- ·Known copper allergy or Wilson's disease
PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
AHK-Cu
- ·Broken or inflamed skin (increased absorption risk)
- ·Concurrent use of other copper-containing formulations
PNC-27
—05Administration Protocol
Parameter
AHK-Cu
PNC-27
1. Topical application
Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Frequency
Once or twice daily. Evening application preferred for overnight contact time.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Scalp preparation
For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Storage
Room temperature, protected from light. Copper complexes may degrade in UV exposure.
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.
5. Duration
Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.
—
06Stack Synergy
AHK-Cu
+ GHK-Cu
ModerateBoth tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.
- AHK-Cu
- 0.001–0.01% topical · AM
- GHK-Cu
- 0.001–0.01% topical · PM
- Frequency
- Daily alternation or combined formulation
- Primary benefit
- Comprehensive dermal regeneration, angiogenesis, hair follicle support
PNC-27
— no documented stacks